An in-vivo pilot study into the effects of FDG-mNP in cancer in mice

• Published in: PloS one 2018-08, Vol.13 (8), p.e0202482
• Main Authors: Aras, Omer, Pearce, Gillian, Watkins, Adam J, Nurili, Fuad, Medine, Emin Ilker, Guldu, Ozge Kozgus, Tekin, Volkan, Wong, Julian, Ma, Xianghong, Ting, Richard, Unak, Perihan, Akin, Oguz
• Format: Article
• Language: English
• Subjects: Animal tissues; Animals; Applied physics; Biocompatibility; Biology and Life Sciences; Brain; Breast cancer; Cancer; Cancer research; Cancer therapies; Cardiovascular disease; Chemotherapy; Childrens health; Engineering and Technology; Fever; Glucose; Glucose-6-Phosphate - analogs & derivatives; Glucose-6-Phosphate - pharmacokinetics; Glucose-6-Phosphate - pharmacology; Gynecology; Hyperthermia; Hyperthermia, Induced; Injection; Intravenous administration; Kidneys; Liver; Lungs; Lymph nodes; Magnetite; Magnetite Nanoparticles - therapeutic use; Male; Medical imaging; Medical research; Medicine and Health Sciences; Metabolism; Mice; Nanoparticles; Neoplasms, Experimental - metabolism; Neoplasms, Experimental - pathology; Neoplasms, Experimental - therapy; Neuroblastoma; NMR; Nuclear magnetic resonance; Obstetrics; Organ Specificity; Organs; Pilot Projects; Prostate; Prostate cancer; Prostatic Neoplasms - metabolism; Prostatic Neoplasms - pathology; Prostatic Neoplasms - therapy; Radiation therapy; Research and Analysis Methods; Skin cancer; Spleen; Studies; Tumors
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0202482

Previously, fluorodeoxy glucose conjugated magnetite nanoparticles (FDG-mNPs) injected into cancer cells in conjunction with the application of magnetic hyperthermia have shown promise in new FDG-mNPs applications. The aim of this study was to determine potential toxic or unwanted effects involving both tumour cells and normal tissue in other organs when FDG-mNPs are administered intravenously or intratumourally in mice. FDG-mNPs were synthesized. A group of six prostate-tumour bearing mice were injected with 23.42 mg/ml FDG-mNPs (intravenous injection, n = 3; intratumoural injection into the prostate tumour, n = 3). Mice were euthanized and histological sampling of tissue was conducted for the prostate tumour, as well as for lungs, lymph nodes, liver, kidneys, spleen, and brain, at 1 hour (n = 2) and 7 days (n = 4) post-injection. A second group of two normal (non-cancerous) mice received the same injection intravenously into the tail vein and were euthanised at 3 and 6 months post-injection, respectively, to investigate if FDG-mNPs remained in organs at those time points. In prostate-tumour bearing mice, FDG-mNPs concentrated in the prostate tumour, while relatively small amounts were found in the organs of other tissues, particularly the spleen and the liver; FDG-mNP concentrations decreased over time in all tissues. In normal mice, no detrimental effects were found in either mouse at 3 or 6 months. Intravenous or intratumoural FDG-mNPs can be safely administered for effective cancer cell destruction. Further research on the clinical utility of FDG-mNPs will be conducted by applying hyperthermia in conjunction with FDG-mNPs in mice.